ID

31156

Descrizione

A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib); ODM derived from: https://clinicaltrials.gov/show/NCT00854308

collegamento

https://clinicaltrials.gov/show/NCT00854308

Keywords

versioni (1)
  1. 23/07/18 23/07/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

23 luglio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Non-Small Cell Lung Cancer NCT00854308

Inglese

Eligibility Non-Small Cell Lung Cancer NCT00854308

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must meet the following criteria for study entry:
Descrizione

Criteria Fulfill

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
histologically confirmed nsclc
Descrizione

Non-Small Cell Lung Carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0007131
availability of a tumor specimen
Descrizione

Availability of Tumor tissue sample

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C0475358
recurrent or progressive disease following at least one chemo containing regimen for stage iiib/iv disease
Descrizione

Recurrent disease | Progressive Disease | Chemotherapy Quantity Disease TNM clinical staging

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0277556
UMLS CUI [2]
C1335499
UMLS CUI [3,1]
C0392920
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0012634
UMLS CUI [3,4]
C3258246
measurable disease in accordance with response evaluation criteria in solid tumors (recist)
Descrizione

Measurable Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
at least one measurable lesion on a pre-treatment 18-fluorodeoxyglcose−positron emission tomography (fdg-pet) scan that is also a target lesion on computed tomography (ct) according to recist
Descrizione

Measurable lesion Quantity FDG-PET Pretreatment | Target Lesion CT

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C3641247
UMLS CUI [1,4]
C3539075
UMLS CUI [2,1]
C2986546
UMLS CUI [2,2]
C0040405
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
more than two prior treatments for stage iiib/iv
Descrizione

Prior Therapy Quantity TNM clinical staging

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C3258246
more than 30 days of exposure to an investigational or marketed agent that can act by egfr inhibition, or a known epidermal growth factor receptor (egfr)-related toxicity resulting in dose modifications
Descrizione

Exposure to EGFR inhibitor | Toxicity EGFR Related | Toxicity Resulting in Dose Modification

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C1443775
UMLS CUI [2,1]
C0600688
UMLS CUI [2,2]
C0034802
UMLS CUI [2,3]
C0439849
UMLS CUI [3,1]
C0600688
UMLS CUI [3,2]
C0332294
UMLS CUI [3,3]
C1707811
chemotherapy, biologic therapy, radiotherapy or investigational drug within 28 days prior to randomization
Descrizione

Chemotherapy | Biological treatment | Therapeutic radiology procedure | Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1531518
UMLS CUI [3]
C1522449
UMLS CUI [4]
C0013230
untreated and/or active (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) central nervous system (cns) metastasis
Descrizione

CNS metastases untreated | CNS metastases Progressive | CNS metastases Requirement Control Symptomatic | CNS metastases Requirement Anticonvulsants | CNS metastases Requirement Adrenal Cortex Hormones

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0205329
UMLS CUI [3,1]
C0686377
UMLS CUI [3,2]
C1514873
UMLS CUI [3,3]
C0243148
UMLS CUI [3,4]
C0231220
UMLS CUI [4,1]
C0686377
UMLS CUI [4,2]
C1514873
UMLS CUI [4,3]
C0003286
UMLS CUI [5,1]
C0686377
UMLS CUI [5,2]
C1514873
UMLS CUI [5,3]
C0001617
history of serious systemic disease within the past 6 months prior to randomization
Descrizione

Systemic disease Serious

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0442893
UMLS CUI [1,2]
C0205404
uncontrolled diabetes
Descrizione

Diabetic - poor control

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0421258
major surgical procedure or significant traumatic injury within 28 days prior to randomization
Descrizione

Major surgery | Traumatic injury

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2]
C3263723
anticipation of need for a major surgical procedure during the course of the study
Descrizione

Anticipation Patient need for Major surgery

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0679106
UMLS CUI [1,2]
C0686904
UMLS CUI [1,3]
C0679637
local palliative radiotherapy within 7 days prior to randomization or persistent adverse effects from radiotherapy that have not been resolved to grade ii or less prior to randomization
Descrizione

Palliative course of radiotherapy Local | Adverse effect of radiation therapy Persistent | Absence Resolution CTCAE grades

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0475092
UMLS CUI [1,2]
C0205276
UMLS CUI [2,1]
C0392615
UMLS CUI [2,2]
C0205322
UMLS CUI [3,1]
C0332197
UMLS CUI [3,2]
C1514893
UMLS CUI [3,3]
C1516728
symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
Descrizione

Hypercalcemia Symptomatic | Requirement Diphosphonates

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020437
UMLS CUI [1,2]
C0231220
UMLS CUI [2,1]
C1514873
UMLS CUI [2,2]
C0012544
Ritorna all'inizio della pagina

Similar models

Eligibility Non-Small Cell Lung Cancer NCT00854308

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Criteria Fulfill
Item
patients must meet the following criteria for study entry:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Non-Small Cell Lung Carcinoma
Item
histologically confirmed nsclc
boolean
C0007131 (UMLS CUI [1])
Availability of Tumor tissue sample
Item
availability of a tumor specimen
boolean
C0470187 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
Recurrent disease | Progressive Disease | Chemotherapy Quantity Disease TNM clinical staging
Item
recurrent or progressive disease following at least one chemo containing regimen for stage iiib/iv disease
boolean
C0277556 (UMLS CUI [1])
C1335499 (UMLS CUI [2])
C0392920 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0012634 (UMLS CUI [3,3])
C3258246 (UMLS CUI [3,4])
Measurable Disease
Item
measurable disease in accordance with response evaluation criteria in solid tumors (recist)
boolean
C1513041 (UMLS CUI [1])
Measurable lesion Quantity FDG-PET Pretreatment | Target Lesion CT
Item
at least one measurable lesion on a pre-treatment 18-fluorodeoxyglcose−positron emission tomography (fdg-pet) scan that is also a target lesion on computed tomography (ct) according to recist
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C3641247 (UMLS CUI [1,3])
C3539075 (UMLS CUI [1,4])
C2986546 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Prior Therapy Quantity TNM clinical staging
Item
more than two prior treatments for stage iiib/iv
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,3])
Exposure to EGFR inhibitor | Toxicity EGFR Related | Toxicity Resulting in Dose Modification
Item
more than 30 days of exposure to an investigational or marketed agent that can act by egfr inhibition, or a known epidermal growth factor receptor (egfr)-related toxicity resulting in dose modifications
boolean
C0332157 (UMLS CUI [1,1])
C1443775 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C0034802 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0600688 (UMLS CUI [3,1])
C0332294 (UMLS CUI [3,2])
C1707811 (UMLS CUI [3,3])
Chemotherapy | Biological treatment | Therapeutic radiology procedure | Investigational New Drugs
Item
chemotherapy, biologic therapy, radiotherapy or investigational drug within 28 days prior to randomization
boolean
C0392920 (UMLS CUI [1])
C1531518 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
CNS metastases untreated | CNS metastases Progressive | CNS metastases Requirement Control Symptomatic | CNS metastases Requirement Anticonvulsants | CNS metastases Requirement Adrenal Cortex Hormones
Item
untreated and/or active (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) central nervous system (cns) metastasis
boolean
C0686377 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0205329 (UMLS CUI [2,2])
C0686377 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
C0243148 (UMLS CUI [3,3])
C0231220 (UMLS CUI [3,4])
C0686377 (UMLS CUI [4,1])
C1514873 (UMLS CUI [4,2])
C0003286 (UMLS CUI [4,3])
C0686377 (UMLS CUI [5,1])
C1514873 (UMLS CUI [5,2])
C0001617 (UMLS CUI [5,3])
Systemic disease Serious
Item
history of serious systemic disease within the past 6 months prior to randomization
boolean
C0442893 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
Diabetic - poor control
Item
uncontrolled diabetes
boolean
C0421258 (UMLS CUI [1])
Major surgery | Traumatic injury
Item
major surgical procedure or significant traumatic injury within 28 days prior to randomization
boolean
C0679637 (UMLS CUI [1])
C3263723 (UMLS CUI [2])
Anticipation Patient need for Major surgery
Item
anticipation of need for a major surgical procedure during the course of the study
boolean
C0679106 (UMLS CUI [1,1])
C0686904 (UMLS CUI [1,2])
C0679637 (UMLS CUI [1,3])
Palliative course of radiotherapy Local | Adverse effect of radiation therapy Persistent | Absence Resolution CTCAE grades
Item
local palliative radiotherapy within 7 days prior to randomization or persistent adverse effects from radiotherapy that have not been resolved to grade ii or less prior to randomization
boolean
C0475092 (UMLS CUI [1,1])
C0205276 (UMLS CUI [1,2])
C0392615 (UMLS CUI [2,1])
C0205322 (UMLS CUI [2,2])
C0332197 (UMLS CUI [3,1])
C1514893 (UMLS CUI [3,2])
C1516728 (UMLS CUI [3,3])
Hypercalcemia Symptomatic | Requirement Diphosphonates
Item
symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
boolean
C0020437 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C1514873 (UMLS CUI [2,1])
C0012544 (UMLS CUI [2,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial